生物模拟市场规模、份额、趋势分析报告产品（软件、服务）、应用（药物开发、药物发现）、最终应用、地区、细分预测，2022-2030

生物模拟市场的增长和趋势

根据 Grand View Research, Inc. 的一份新报告，预计到 2030 年，全球生物模拟市场规模将达到 99.5 亿美元。

从 2022 年到 2030 年，市场预计将以 16.9% 的复合年增长率增长。市场增长的关键因素包括慢性病发病率的增加、医疗保健数字化程度的提高以及生物模拟解决方案在临床试验和研究中的使用。

随着急慢性疾病的流行，药物发现开发的需求增加，研发活动的资金分配增加，生物模拟解决方案的采用得到促进。此外，由于药物减量率高导致临床试验成本增加，预计采用计算机生物学方法将增加临床试验的紧迫性。这种方法可以通过预测生物相互作用来显着降低药物失败的可能性并降低总体成本。

由于药物復发率的增加、耐药病例的增加以及治疗艾滋病等疾病的药物供应受到限制，临床上可以将生物模拟应用于药物开发和药物发现等应用。它的要求越来越高。

COVID-19 大流行也对市场增长产生了重大影响。例如，Simulations Plus 于 2020 年 3 月启动了 Strategies Plus COVID-19 ACT 计划，以加快向所有参与 COVID-19 研究的组织提供咨询援助。截至 2020 年 11 月，公司已宣布不会对其业务产生重大负面影响。但是，COVID-19 的持续扩张以及受影响国家政府采取的措施可能会扰乱供应链并对公司的业务和财务状况产生不利影响。

对生物模拟软件和服务的需求不断增长，也是由于其高成本效益。生物模拟解决方案可以在产品开发的早期经济有效地预测研究药物的毒性、副作用和疗效，降低后期药物復发和不良事件的概率。

市场参与者正在投资于许多战略举措，例如收购、合併、合作伙伴关係和产品发布，以保持市场竞争力。例如，2022 年 1 月，Simulations Plus Inc. 与一家兽医公司合作，验证当前的动物生理药代动力学 (PBPK) 模型。通过这项资助合作，该公司寻求在 GastroPlus 平台上添加一个重要的新物种。此外，2021年11月，横河电机有限公司收购了德国Insilico Biotechnology AG，该公司开发和提供生物工艺软件和服务。

生物模拟市场报告亮点

• 按产品划分，软件在 2021 年占据市场主导地位。这可能是由于满足研究要求的各种特定应用软件的可用性。此外，生物模拟软件用于临床试验，以促进建模和目标药物识别。
• 2021 年，药物开发使用部分的收入份额将超过 55.0%。
• 由于战略计划的增加，製药和生物技术公司的最终用途将在 2021 年占据最大的收入份额。
• 2021 年，北美收入占比最高，超过 45.0%。有利的医疗费用框架（特别是在实施《健康保险改革法案》之后）和先进的医疗基础设施的存在预计将在预测期内推动该地区的市场。
• 由于 CRO 数量增加、医疗保健 IT 支出增加以及医疗保健基础设施快速发展，预计亚太地区将在预测期内显着增长。

目录

第 1 章调查方法及范围

• 市场细分和范围
  • 细分范围
  • 区域范围
  • 时间线估计/预测
• 调查方法
• 资讯采购
  • 购买的数据库：
  • GVR 内部数据库
  • 二次材料
  • 初步调查
  • 初步调查详情
• 资讯或数据分析
  • 数据分析模型
• 市场製定与验证
• 型号详情
• 二次材料清单
• 目的
  • 目的 1
  • 目的 2
  • 目的 3
  • 目的 4

第 2 章执行摘要

• 生物模拟市场概况

第 3 章生物模拟市场的变量、趋势和范围

• 生物模拟市场细分和范围
• 生物模拟市场动态
  • 市场促进因素分析
  • 影响分析
    • 在药品监管审批流程中越来越多地采用基于生理学的药代动力学模型
    • 耐药性增加导致復发病例增加
    • 不断进步的技术进步
    • 越来越需要降低药物发现和开发成本
    • 加快配方开发并节省昂贵的研究费用
    • 增加对生命科学行业的投资
    • 增加使用个性化医疗
  • 市场资讯分析
  • 影响分析
    • 缺乏标准化
    • 缺乏熟练的专业人员
    • 知识产权保护和公共政策问题
• 2021 年渗透率和增长前景图
• 价格分析
• 生物模拟市场分析工具：Porter
  • 供应商议价能力：低
  • 买方议价能力：中等
  • 替代治疗：低
  • 新进入者的威胁：高
  • 竞争对手之间的敌对关係：高
• 基于因素的 SWOT 分析（政治和法律、经济和技术）
  • 政治/法律状况
  • 经济形势
  • 技术情况

第 4 章生物模拟市场：COVID-19 的影响

• COVID-19 对生物模拟市场的影响
  • 当前和未来的影响分析
  • COVID-19 对市场参与者的影响
  • 疾病流行分析

第 5 章生物模拟市场：细分分析，产品，2017-2030

• 定义和范围
• 2021 年和 2030 年产品市场份额分析
• 2017-2030 年生物模拟市场，按产品分类
• 软件
  • 2017-2030 年软件市场
• 服务
  • 2017-2030年服务市场
  • 内部服务
    • 2017-2030年内部服务市场
  • 合同服务
    • 2017-2030 年合同服务市场

第 6 章生物模拟市场：细分分析，按应用，2017-2030

• 定义和范围
• 2021 年和 2030 年应用市场份额分析
• 生物模拟市场，按应用，2017-2030
• 药物开发
  • 2017-2030年药物开发市场
• 药物发现
  • 2017-2030 年药物发现市场
• 其他
  • 其他市场，2017-2030

第 7 章生物模拟市场：细分分析，按最终用途，2017-2030

• 定义和范围
• 2021 年和 2030 年最终用途市场份额分析
• 2017-2030 年全球生物模拟市场，按最终用途分类
• 製药和生物技术公司
  • 2017-2030年医药及生物科技企业市场
• CRO
  • 2017-2030 年 CRO 市场
• 调节器
  • 监管市场，2017-2030
• 学术研究所
  • 2017-2030 年学术研究机构市场

第 8 章生物模拟市场：2017-2030 年区域市场分析

• 定义和范围
• 2021 年和 2030 年区域市场份额分析
• 区域市场概况
• 2017-2030 年市场规模、预测和趋势分析
• 北美
  • 2021 年按国家/地区分列的北美生物模拟市场份额分析
  • 美国
    • 2017-2030年美国生物模拟市场
  • 加拿大
    • 2017-2030 年加拿大生物模拟市场
• 欧洲
  • 2021 年欧洲生物模拟市场份额分析，按国家/地区分列
  • 英国
    • 2017-2030 年英国生物模拟市场
  • 德国
    • 2017-2030 年德国生物仿真市场
  • 法国
    • 2017-2030 年法国生物模拟市场
• 亚太地区
  • 亚太地区生物模拟市场份额分析，国家，2021
  • 日本
    • 2017-2030年日本生物仿真市场
  • 中国
    • 2017-2030年中国生物模拟市场
  • 印度
    • 印度生物模拟市场，2017-2030
• 拉丁美洲
  • 拉丁美洲生物模拟市场份额分析，国家，2021
  • 巴西
    • 2017-2030 年巴西生物模拟市场
  • 墨西哥
    • 2017-2030 年墨西哥生物模拟市场
• 多边环境协定
  • MEA 生物模拟市场份额分析，国家，2021
  • 南非
    • 2017-2030 年南非生物模拟市场

第 9 章生物仿真市场-竞争分析

• 战略框架
• 市场参与者的分类
• 上市公司
  • 公司市场分析
  • 产品类别对比分析
• 私人公司
  • 私营公司名单
  • 亚太区初创企业名单

第 10 章生物模拟市场-公司简介

• Certara, USA
  • 公司简介
  • 财务表现
  • 产品基准
  • 战略举措
• Simulations Plus
  • 公司简介
  • 财务表现
  • 产品基准
  • 战略举措
• Dassault Systemes
  • 公司简介
  • 财务表现
  • 产品基准
  • 战略举措
• Schrodinger, Inc.
  • 公司简介
  • 财务表现
  • 产品基准
  • 战略举措
• Advanced Chemistry Development
  • 公司简介
  • 产品基准
  • 战略举措
• Chemical Computing Group ULC
  • 公司简介
  • 财务表现
  • 产品基准
  • 战略举措
• Physiomics Plc
  • 公司简介
  • 财务表现
  • 产品基准
  • 战略举措
• Rosa & Co. LLC
  • 公司简介
  • 产品基准
  • 战略举措
• Biosimulation Consulting Inc.
  • 公司简介
  • 财务表现
  • 服务基准
• Genedata AG
  • 公司简介
  • 财务表现
  • 产品基准
  • 战略举措
• Instem Group of Companies
  • 公司简介
  • 财务表现
  • 产品基准
  • 战略举措
• PPD, Inc.
  • 公司简介
  • 财务表现
  • 服务基准
  • 战略举措
• Yokogawa Insilico Biotechnology GmbH
  • 公司简介
  • 产品基准
  • 战略举措
• Immunetrics
  • 公司简介
  • 产品基准

第11章KOL评论

Biosimulation Market Growth & Trends:

The global biosimulation market size is expected to reach USD 9.95 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 16.9% from 2022 to 2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

Biosimulation Market Report Highlights:

• By product, software dominated the market in 2021. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and targets drug identification

• The drug development application segment accounted for the largest revenue share of more than 55.0% in 2021

• By end-use, pharmaceutical and biotechnology companies held the largest revenue share in 2021 due to the increasing strategic initiatives

• North America grabbed the largest revenue share of over 45.0% in 2021. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure are expected to drive the regional market over the forecast period

• The Asia Pacific region is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 segment scope
  • 1.1.2 regional scope
  • 1.1.3 Estimates and forecast timeline
• 1.2 Research Methodology
• 1.3 Information procurement
  • 1.3.1 Purchased database:
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
• 1.7 List of Secondary Sources
• 1.8 Objectives
  • 1.8.1 Objective 1
  • 1.8.2 Objective 2
  • 1.8.3 Objective 3
  • 1.8.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Biosimulation Market Summary

Chapter 3 Biosimulation Market Variables, Trends & Scope

• 3.1 Biosimulation Market Segmentation and Scope
• 3.2 Biosimulation Market Dynamics
  • 3.2.1 Market driver analysis
  • 3.2.2 Impact analysis
    • 3.2.2.1 Increasing adoption of Physiologically Based Pharmacokinetic Modeling in the regulatory approval process of drugs
    • 3.2.2.2 Growing number of relapse cases due to increasing drug resistance
    • 3.2.2.3 Rising Technological advancements
    • 3.2.2.4 Increasing need to reduce drug discovery and development costs
    • 3.2.2.5 accelerating formulation development and saving costly studies
    • 3.2.2.6 Increasing investments in the life sciences industry
    • 3.2.2.7 Increasing use of personalized medicine
  • 3.2.3 Market restraint analysis
  • 3.2.4 Impact analysis
    • 3.2.4.1 Lack of standardization
    • 3.2.4.2 Shortage of skilled professionals
    • 3.2.4.3 Intellectual property protection and public policy issues
• 3.3 Penetration and Growth Prospect Mapping, 2021
• 3.4 Pricing Analysis
• 3.5 Biosimulation Market Analysis Tools: Porters
  • 3.5.1 bargaining power of Suppliers: Low
  • 3.5.2 bargaining power of Buyers: Moderate
  • 3.5.3 Therat of Substitutes: Low
  • 3.5.4 Threat of New Entrants: High
  • 3.5.5 Competitive Rivalry: High
• 3.6 SWOT Analysis by Factors (Political & Legal, Economic, and Technological)
  • 3.6.1 Political/Legal Landscape
  • 3.6.2 Economic Landscape
  • 3.6.3 Technology Landscape

Chapter 4 Biosimulation Market: Impact of COVID-19

• 4.1 Impact of Covid-19 on the Biosimulation Market
  • 4.1.1 Current And Future Impact Analysis
  • 4.1.2 Impact of covid-19 on market players
  • 4.1.3 Disease Prevalence Analysis

Chapter 5 Biosimulation Market: Segment Analysis, By Product, 2017 - 2030 (USD Million)

• 5.1 Definition and Scope
• 5.2 Product Market Share Analysis, 2021 & 2030
• 5.3 Biosimulation Market, by Product, 2017 - 2030
• 5.4 Software
  • 5.4.1 software market, 2017 - 2030 (USD Million)
• 5.5 Services
  • 5.5.1 Services market, 2017 - 2030 (USD Million)
  • 5.5.2 In-house Services
    • 5.5.2.1 In-house Services market, 2017 - 2030 (USD Million)
  • 5.5.3 Contract Services
    • 5.5.3.1 Contract Services market, 2017 - 2030 (USD Million)

Chapter 6 Biosimulation Market: Segment Analysis, By Application, 2017 - 2030 (USD Million)

• 6.1 Definition and Scope
• 6.2 Application Market Share Analysis, 2021 & 2030
• 6.3 Biosimulation Market, by Application, 2017 - 2030
• 6.4 Drug Development
  • 6.4.1 drug development market, 2017 - 2030 (USD Million)
• 6.5 Drug Discovery
  • 6.5.1 Drug Discovery market, 2017 - 2030 (USD Million)
• 6.6 Others
  • 6.6.1 Others market, 2017 - 2030 (USD Million)

Chapter 7 Biosimulation Market: Segment Analysis, By End-use, 2017 - 2030 (USD Million)

• 7.1 Definition and Scope
• 7.2 End-use Market Share Analysis, 2021 & 2030
• 7.3 Global Biosimulation Market, by End-use, 2017 - 2030
• 7.4 Pharmaceutical & Biotechnology Companies
  • 7.4.1 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million)
• 7.5 CROs
  • 7.5.1 CROs market, 2017 - 2030 (USD million)
• 7.6 Regulatory Authorities
  • 7.6.1 Regulatory authorities market, 2017 - 2030 (USD Million)
• 7.7 Academic Research Institutions
  • 7.7.1 Academic research institutions market, 2017 - 2030 (USD million)

Chapter 8 Biosimulation Market: Regional Market Analysis 2017 - 2030 (USD Million)

• 8.1 Definition & Scope
• 8.2 Regional Market Share Analysis, 2021 & 2030
• 8.3 Regional Market Snapshot
• 8.4 Market Size, & Forecasts, and Trend Analysis, 2017 - 2030
• 8.5 North America
  • 8.5.1 North America Biosimulation Market Share Analysis, By Country, 2021
  • 8.5.2 U.S.
    • 8.5.2.1 U.S. Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.5.3 Canada
    • 8.5.3.1 Canada Biosimulation Market, 2017 - 2030 (USD Million)
• 8.6 Europe
  • 8.6.1 Europe Biosimulation Market Share Analysis, By Country, 2021
  • 8.6.2 U.K.
    • 8.6.2.1 U.K. Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.6.3 Germany
    • 8.6.3.1 Germany Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.6.4 France
    • 8.6.4.1 France Biosimulation Market, 2017 - 2030 (USD Million)
• 8.7 Asia Pacific
  • 8.7.1 Asia Pacific Biosimulation Market Share Analysis, By Country, 2021
  • 8.7.2 Japan
    • 8.7.2.1 Japan Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.7.3 China
    • 8.7.3.1 China Biosimulation Market, 2017 - 2030 (USD million)
  • 8.7.4 India
    • 8.7.4.1 India Biosimulation Market, 2017 - 2030 (USD Million)
• 8.8 Latin America
  • 8.8.1 Latin America Biosimulation Market Share Analysis, By Country, 2021
  • 8.8.2 Brazil
    • 8.8.2.1 Brazil Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.8.3 Mexico
    • 8.8.3.1 Mexico Biosimulation Market, 2017 - 2030 (USD Million)
• 8.9 MEA
  • 8.9.1 MEA Biosimulation Market Share Analysis, By Country, 2021
  • 8.9.2 South Africa
    • 8.9.2.1 South Africa Biosimulation Market, 2017 - 2030 (USD Million)

Chapter 9 Biosimulation Market - Competitive Analysis

• 9.1 Strategy Framework
• 9.2 Market Participant Categorization
• 9.3 Public Companies
  • 9.3.1 Company market position analysis
  • 9.3.2 Comparative analysis by product category
• 9.4 Private Companies
  • 9.4.1 List of Private companies
  • 9.4.2 List of Emerging companies in the Asia Pacific Region

Chapter 10 Biosimulation Market - Company Profiles

• 10.1 Certara, USA
  • 10.1.1 Company overview
  • 10.1.2 Financial performance
  • 10.1.3 Product benchmarking
  • 10.1.4 Strategic initiatives
• 10.2 Simulations Plus
  • 10.2.1 Company overview
  • 10.2.2 Financial performance
  • 10.2.3 Product benchmarking
  • 10.2.4 Strategic initiatives
• 10.3 Dassault Systemes
  • 10.3.1 Company overview
  • 10.3.2 Financial performance
  • 10.3.3 Product benchmarking
  • 10.3.4 Strategic initiatives
• 10.4 Schrodinger, Inc.
  • 10.4.1 Company overview
  • 10.4.2 Financial performance
  • 10.4.3 Product benchmarking
  • 10.4.4 Strategic initiatives
• 10.5 Advanced Chemistry Development
  • 10.5.1 Company overview
  • 10.5.2 Product benchmarking
  • 10.5.3 Strategic initiatives
• 10.6 Chemical Computing Group ULC
  • 10.6.1 Company overview
  • 10.6.2 Financial performance
  • 10.6.3 Product benchmarking
  • 10.6.4 Strategic initiatives
• 10.7 Physiomics Plc
  • 10.7.1 Company overview
  • 10.7.2 Financial performance
  • 10.7.3 Product benchmarking
  • 10.7.4 Strategic initiatives
• 10.8 Rosa & Co. LLC
  • 10.8.1 Company overview
  • 10.8.2 Product benchmarking
  • 10.8.3 Strategic initiatives
• 10.9 Biosimulation Consulting Inc.
  • 10.9.1 Company overview
  • 10.9.2 Financial performance
  • 10.9.3 Service benchmarking
• 10.10 Genedata AG
  • 10.10.1 Company overview
  • 10.10.2 Financial performance
  • 10.10.3 Product benchmarking
  • 10.10.4 Strategic initiatives
• 10.11 Instem Group of Companies
  • 10.11.1 Company overview
  • 10.11.2 Financial performance
  • 10.11.3 Product benchmarking
  • 10.11.4 Strategic initiatives
• 10.12 PPD, Inc.
  • 10.12.1 Company overview
  • 10.12.2 Financial performance
  • 10.12.3 Service benchmarking
  • 10.12.4 Strategic initiatives
• 10.13 Yokogawa Insilico Biotechnology GmbH
  • 10.13.1 Company overview
  • 10.13.2 Product benchmarking
  • 10.13.3 Strategic initiatives
• 10.14 Immunetrics
  • 10.14.1 Company overview
  • 10.14.2 Product benchmarking

Chapter 11 KOL Commentary

List of Tables

• Table 1 List of secondary sources
• Table 2 List of products for major companies
• Table 3 List of private companies
• Table 4 List of emerging companies
• Table 5 North America biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 6 North America biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 7 North America biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 8 North America biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 9 North America biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 10 U.S. biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 11 U.S. biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 12 U.S. biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 13 U.S. biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 14 Canada biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 15 Canada biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 16 Canada biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 17 Canada biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 18 Europe biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 19 Europe biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 20 Europe biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 21 Europe biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 22 Europe biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 23 Germany biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 24 Germany biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 25 Germany biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 26 Germany biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 27 U.K. biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 28 U.K. biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 29 U.K. biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 30 U.K. biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 31 France biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 32 France biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 33 France biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 34 France biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 35 Asia Pacific biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 36 Asia Pacific biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 37 Asia Pacific biosimulation services market, by type, 2017 - 2030(USD Million)
• Table 38 Asia Pacific biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 39 Asia Pacific biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 40 Japan biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 41 Japan biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 42 Japan biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 43 Japan biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 44 China biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 45 China biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 46 China biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 47 China biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 48 India biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 49 India biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 50 India biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 51 India biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 52 Latin America biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 53 Latin America biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 54 Latin America biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 55 Latin America biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 56 Latin America biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 57 Brazil biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 58 Brazil biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 59 Brazil biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 60 Brazil biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 61 Mexico biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 62 Mexico biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 63 Mexico biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 64 Mexico biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 65 MEA biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 66 MEA biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 67 MEA biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 68 MEA biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 69 MEA biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 70 South Africa biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 71 South Africa biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 72 South Africa biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 73 South Africa biosimulation market, by end-use, 2017 - 2030 (USD Million)

List of Figures

• Fig. 1 Biosimulation market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Commodity Flow Analysis
• Fig. 9 Biosimulation Market outlook (2021, USD Million)
• Fig. 10 Biosimulation market segmentation and scope
• Fig. 11 Biosimulation market dynamics analysis
• Fig. 12 Biosimulation market driver and restraints impact analysis
• Fig. 13 Biosimulation market driver analysis
• Fig. 14 Biosimulation market drivers impact analysis
• Fig. 15 R&D expenditures by various market players in 2021 (USD Million)
• Fig. 16 Biosimulation market restraint impact
• Fig. 17 Biosimulation market restraint impact analysis
• Fig. 18 Penetration & growth prospect mapping
• Fig. 19 COVID-19 new cases in major 35 countries around the world
• Fig. 20 Biosimulation market: Product movement analysis
• Fig. 21 Biosimulation market product outlook: Key takeaways
• Fig. 22 Software market, 2017 - 2030 (USD Million)
• Fig. 23 Services market, 2017 - 2030 (USD Million)
• Fig. 24 In-house Services market, 2017 - 2030 (USD Million)
• Fig. 25 Contract Services market, 2017 - 2030 (USD Million)
• Fig. 26 Biosimulation market: Application movement analysis
• Fig. 27 Biosimulation market application outlook: Key takeaways
• Fig. 28 Drug development market, 2017 - 2030 (USD Million)
• Fig. 29 Drug discovery market, 2017 - 2030 (USD Million)
• Fig. 30 Others market, 2017 - 2030 (USD Million)
• Fig. 31 Biosimulation market: End-use movement analysis
• Fig. 32 Biosimulation market end-use outlook: Key takeaways
• Fig. 33 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million)
• Fig. 34 CROs market, 2017 - 2030 (USD Million)
• Fig. 35 Regulatory authorities market, 2017 - 2030 (USD Million)
• Fig. 36 Academic research institutions market, 2017 - 2030 (USD Million)
• Fig. 37 Regional outlook, 2021 & 2030
• Fig. 38 Regional marketplace: Key takeaways
• Fig. 39 North America Biosimulation market share, by country, 2021
• Fig. 40 U.S. biosimulation market, 2017 - 2030 (USD Million)
• Fig. 41 Canada biosimulation market, 2017 - 2030 (USD Million)
• Fig. 42 Europe biosimulation market share analysis, by country, 2021
• Fig. 43 U.K. Biosimulation market, 2017 - 2030 (USD Million)
• Fig. 44 Germany biosimulation market, 2017 - 2030 (USD Million)
• Fig. 45 France biosimulation market, 2017 - 2030 (USD Million)
• Fig. 46 Asia Pacific biosimulation market share analysis, by country, 2021
• Fig. 47 Japan biosimulation market, 2017 - 2030 (USD Million)
• Fig. 48 China biosimulation market, 2017 - 2030 (USD Million)
• Fig. 49 India biosimulation market, 2017 - 2030 (USD Million)
• Fig. 50 Latin America Biosimulation market share analysis, by country, 2021
• Fig. 51 Brazil biosimulation market, 2017 - 2030 (USD Million)
• Fig. 52 Mexico Biosimulation market, 2017 - 2030 (USD Million)
• Fig. 53 MEA biosimulation market share analysis, by country, 2021
• Fig. 54 South Africa biosimulation market, 2017 - 2030 (USD Million)
• Fig. 55 Strategy framework
• Fig. 56 Market participant categorization
• Fig. 57 Biosimulation: Heat Map Analysis
• Fig. 58 Biosimulation market: Application-wise product ranking